Company intelligence / Profile preview

Achilles Medical

London, United Kingdom

Ownership: Private
Employees: ~180
Development stage: Other

Overview

Achilles Therapeutics is a clinical-stage biopharmaceutical company developing personalized T cell therapies for solid tumors. The company utilizes its proprietary PELEUS bioinformatics platform to identify clonal neoantigens—unique mutations present in all of a patient's tumor cells but not in healthy tissue. Their lead product candidates, derived from the patient's own T cells, are designed to target these clonal neoantigens to achieve a more potent and durable anti-tumor response. Achilles is currently evaluating its therapies in clinical trials for non-small cell lung cancer and melanoma.

Therapeutic areas: Oncology
Modalities: Cell therapyT cell receptor engineered T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Achilles Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Achilles Medical.

Explore the full profile